# CONTENTS

<table>
<thead>
<tr>
<th>FOREWORD</th>
<th>xiii</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF CONTRIBUTORS</td>
<td>xiv</td>
</tr>
</tbody>
</table>

1. BEHAVIORAL RESPONSES TO PSYCHOMOTOR STIMULANT DRUGS: LOCALIZATION IN THE CENTRAL NERVOUS SYSTEM

J. L. Evenden and C. N. Ryan

| 1. Introduction | 1 |
| 2. Techniques | 3 |
| 3. Behavior |
| 3.1 Locomotor Activity | 4 |
| 3.2 Asymmetry and Rotation | 6 |
| 3.3 Schedule-induced Behavior | 7 |
| 3.4 Response Disinhibition | 7 |
| 3.5 Rate Dependent Effects | 8 |
| 3.6 Perseveration and Switching | 8 |
| 3.7 Stereotyped Behavior | 9 |
| 3.8 Conditioned Reinforcement | 10 |
| 3.9 Reinforcement | 11 |
| 3.10 Drug Discrimination | 11 |
| 3.11 Anorectic and Feeding Effects | 12 |
| 3.12 Cognitive Effects | 12 |
| 4. General Discussion | 14 |
| References | 16 |

2. THE ROLE OF REWARD PATHWAYS IN THE DEVELOPMENT OF DRUG DEPENDENCE

Roy A. Wise

| 1. Introduction | 23 |
| 2. Frame of Reference | 25 |
| 3. Pathways of Negative Reinforcement |
| 3.1 Physical Dependence and its Pathways | 26 |
| 3.2 Other Sources of Negative Reinforcement | 30 |
| 4. Pathways of Positive Reinforcement |
| 4.1 The Substrate of Brain Stimulation Reward | 33 |
| 4.2 The Substrates of Food and Water Reward | 36 |
| 4.3 The Substrate of Opiate Reward | 39 |
| 4.4 The Substrate of Psychomotor Stimulant Reward | 40 |
| 4.5 Other Drugs of Abuse | 41 |
| 5. Reward Pathways and Drug “Craving” | 43 |
| 6. Summary and Conclusions | 45 |
| References | 46 |

3. CLASSICAL CONDITIONING AND OPIATE TOLERANCE AND WITHDRAWAL

Shepard Siegel

| 1. Introduction | 59 |
| 2. The Pavlovian Conditioning Situation |
| 2.1 Drugs as Unconditional Stimuli | 60 |
| 2.2 The Pharmacological Conditional Response | 60 |
5 THE MOLECULAR PHARMACOLOGY OF THE MINOR TRANQUILIZERS

Ian L. Martin

1. Introduction 103
2. Gamma-Aminobutyric Acid: Biochemistry and Receptor Pharmacology 104
   2.1 Introduction 104
   2.2 Distribution 104
   2.3 Synthesis and Catabolism 105
   2.4 Uptake 106
   2.5 GABA Receptors 106
   2.6 Summary 109
3. The Mechanism of Action of the Benzodiazepines 109
   3.1 Electrophysiological Studies 109
   3.2 Biochemical Studies 110
4. The Benzodiazepine Receptor 110
   4.1 Initial Radioligand Binding Studies 110
   4.2 Localization 111
   4.3 Phylogeny and Ontogeny 113
5. Characterization of the Benzodiazepine Receptor 113
   5.1 Neurochemical Characterization 113
   5.2 Non-Benzodiazepine Ligands 114
   5.3 Irreversible Labelling 116
   5.4 Kinetics and Thermodynamics of the Binding Interaction 117
   5.5 Multiple Receptors 119
6. Benzodiazepine Receptor Function 121
   6.1 In Vivo Receptor Binding 121
   6.2 Receptor Occupancy and Pharmacological Effect 122
   6.3 In Vitro Measurement of “Function” 122
   6.4 The Three State Model 123
   6.5 Interactions with the Benzodiazepine Receptor 123
   6.6 Endogenous Ligands 126
   6.7 The Neurochemical Consequences of Tolerance and Withdrawal 126
7. Structure Activity Relationships at the Benzodiazepine Receptor 127
8. Biochemical Studies with the Benzodiazepine Receptor 129
   8.1 Solubilization of the Receptor 130
   8.2 Antibodies to the Receptor 131
   8.3 Amino Acid Sequence of the GABA-Benzodiazepine Receptor 131
9. Conclusions and Future Prospects 134

References 134

6 BEHAVIORAL PHARMACOLOGY OF MINOR TRANQUILIZERS

S. E. File and S. Pellow

1. Introduction 147
2. Benzodiazepines as Discriminable Stimuli 147
3. Anxiolytic Actions of Benzodiazepines 148
4. Effects of Benzodiazepines on Stress 149
5. Benzodiazepines and Convulsions 150
6. Benzodiazepines and Aggressive Behavior 152
   6.1 Defensive Behaviors 152
   6.2 Offensive Behaviors 153
7. Benzodiazepines and Exploration 154

References 134
## Contents

8. Effects of Benzodiazepines on Learning and Memory 156
9. Benzodiazepines and Intake of Food or Water 158
10. Benzodiazepine Dependence and Withdrawal 158
11. Rewarding Properties of Minor Tranquilizers 160
12. Tolerance to the Behavioral Effects of Minor Tranquilizers 161
13. Benzodiazepine Effects in the Developing Rat 163
14. Conclusions 165
References 165

7 DEPENDENCE AS A LIMITING FACTOR IN THE CLINICAL USE OF MINOR TRANQUILLIZERS 173

P. Tyrer

1. Introduction 173
2. Evidence for Dependence on Minor Tranquillizers 173
   2.1 Propanediols 173
   2.2 Benzodiazepines 173
3. Factors Predisposing to Benzodiazepine Dependence 176
4. Influence of Dependence on Prescribing Practice 179
   4.1 Frequency of Prescription 179
5. Nature of Drug Prescribed 180
   5.1 Drug Group 180
   5.2 Choice of Benzodiazepine 181
6. Duration of Treatment 182
7. Specific Indications for Treatment 183
   7.1 Anxiety and Insomnia 183
   7.2 Alcoholism 184
   7.3 Tardive Dyskinesia 184
   7.4 Treatment for Medical Disorders 184
8. Summary 185
References 185

8 PHARMACOLOGY OF ETHANOL 189

Larissa A. Pohorecky and John Brick

1. Introduction 189
   1.1 Ethanol 189
   1.2 Ethanol Pharmacokinetics 190
   1.3 Factors Affecting Ethanol Pharmacokinetics 193
   1.4 Alcohol Intoxication 195
   1.5 Conclusions 196
2. Physiological Effects of Ethanol 196
   2.1 Thermoregulation 196
   2.2 Myocardial Effects 198
   2.3 Blood Circulation 204
   2.4 Blood Pressure 206
3. Neurochemical Effects of Ethanol 207
   3.1 Na+/K+ ATPase 208
   3.2 Cyclic Nucleotide System 213
   3.3 Norepinephrine 215
   3.4 Dopamine 223
   3.5 Serotonin 226
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.6 Acetylcholine</td>
<td>228</td>
</tr>
<tr>
<td>3.7 GABA</td>
<td>231</td>
</tr>
<tr>
<td>3.8 Opiates</td>
<td>234</td>
</tr>
<tr>
<td>4. Ethanol and the Endocrine System</td>
<td>236</td>
</tr>
<tr>
<td>4.1 Effect of Acute and Chronic Ethanol</td>
<td>236</td>
</tr>
<tr>
<td>5. Ethanol Tolerance</td>
<td>239</td>
</tr>
<tr>
<td>5.1 Types of Tolerance</td>
<td>240</td>
</tr>
<tr>
<td>5.2 Theories of Tolerance</td>
<td>242</td>
</tr>
<tr>
<td>5.3 Effect of Stress on Tolerance</td>
<td>245</td>
</tr>
<tr>
<td>5.4 Conclusions</td>
<td>245</td>
</tr>
<tr>
<td>6. Ethanol Dependence and Withdrawal</td>
<td>245</td>
</tr>
<tr>
<td>6.1 Alcoholism</td>
<td>245</td>
</tr>
<tr>
<td>6.2 Ethanol Withdrawal Syndrome</td>
<td>246</td>
</tr>
<tr>
<td>6.3 Medical-Physiological Consequences</td>
<td>247</td>
</tr>
<tr>
<td>6.4 Animal Models of 'Alcoholism'</td>
<td>247</td>
</tr>
<tr>
<td>6.5 Conclusions</td>
<td>253</td>
</tr>
<tr>
<td>6. Ethanol Dependence and Withdrawal</td>
<td>245</td>
</tr>
<tr>
<td>6.1 Alcoholism</td>
<td>245</td>
</tr>
<tr>
<td>6.2 Ethanol Withdrawal Syndrome</td>
<td>246</td>
</tr>
<tr>
<td>6.3 Medical-Physiological Consequences</td>
<td>247</td>
</tr>
<tr>
<td>6.4 Animal Models of 'Alcoholism'</td>
<td>247</td>
</tr>
<tr>
<td>6.5 Conclusions</td>
<td>253</td>
</tr>
<tr>
<td>References</td>
<td>254</td>
</tr>
</tbody>
</table>

9 TREATMENT OF ALCOHOL PROBLEMS: WITH SPECIAL REFERENCE TO THE BEHAVIORAL APPROACH 283

Nick Heather

1. Introduction 283
   1.1 Changes in the Scientific Basis of Treatment 283
   1.2 Definitions of Alcohol Problems 284
   1.3 Definitions of Treatment 284
   1.4 Types of Alcohol Problem 284

2. The Development of Treatment Services in Britain 285
   2.1 Modern Developments 285
   2.2 Community Alcohol Teams 286
   2.3 Summary 286

3. Does Treatment for Alcohol Problems Work? 287
   3.1 Spontaneous Remission 288
   3.2 Client Characteristics 288
   3.3 Post-Treatment Factors 289
   3.4 Rejoinders from Treatment Providers 289
   3.5 Effects of the Treatment Debate 290

4. Treatment Approaches and Methods 291
   4.1 Drug Treatments 291
   4.2 Psychotherapy 291
   4.3 Other Treatments 292
   4.4 Alcoholics Anonymous 292

5. The Behavioral Approach to Treatment 293
   5.1 Advantages of the Behavioral Approach 294
   5.2 Aversion Therapy 294
   5.3 Covert Sensitization 295
   5.4 Operant Conditioning 295
   5.5 Disulfiram as a Behavioral Treatment 297
   5.6 Broad Spectrum Treatment 297
   5.7 Stages of Change 299
   5.8 Motivational Interviewing 299
   5.9 Relapse Prevention 300
   5.10 Cue Exposure 301
### 6. Abstinence Versus Controlled Drinking Treatment Goals

6.1 Criteria for Goal Allocation

6.2 Minimal Interventions

7. Future Prospects

References

### 10 ELECTROPHYSIOLOGY OF PSYCHOTOMIMETIC DRUGS

Kurt Rasmussen and George K. Aghajanian

1. Psychedelics
   1.1 Serotonin Disinhibitory Hypothesis
   1.2 Psychedelics as 5-HT$_2$ Agonists

2. Phencyclidine
   2.1 Actions on Monamine-Containing Neurons
   2.2 Interaction with the NMDA-Linked Ion Channel

3. Conclusions

References

### 11 THE BEHAVIORAL PHARMACOLOGY OF STIMULANTS AND HALLUCINOGENS: DRUG DISCRIMINATION AND SELF-ADMINISTRATIONS PROCEDURES

J. Broadbent and J. B. Appel

1. Introduction

2. Psychomotor Stimulants
   2.1 Discriminative Stimulus Properties of Psychomotor Stimulants
   2.2 Self-Administration of Psychomotor Stimulants

3. Hallucinogens: The Discriminative Stimulus Properties of LSD and Mescaline

4. The Behavioral Pharmacology of 3,4-Methylenedioxyamphetamine (MDA) and 3,4-Methylenedioxymethamphetamine (MDMA)

References

### 12 THE CENTRAL NEUROPHARMACOLOGY OF PSYCHOTROPIC CANNABINOIDS

R. G. Pertwee

1. Introduction

2. The Psychopharmacological Effects of Cannabis in Man

3. The Therapeutic Potential of Cannabinoids

4. The Solubility of Cannabinoids

5. Electrophysiological Studies

6. Studies Concerned with Putative Central Neurotransmitters
   6.1 Norepinephrine
   6.2 Dopamine
   6.3 5-Hydroxytryptamine
   6.4 Histamine and Spermidine
   6.5 Acetylcoline
   6.6 Amino Acids and Peptides
   6.7 Binding Studies

7. Studies with Membrane-Bound Enzymes
   7.1 Monoamine Oxidase
   7.2 ATPases
   7.3 Adenylate Cyclase and Guanylate Cyclase
Contents

7.4 Phospholipases A₂ and C, Cyclo-Oxygenase, Lipoxygenase and Thromboxane Synthetase 399

8. Membrane Studies 403
9. Molecular Mechanisms 408
10. General Discussion and Summary
    10.1 The Role of Transmitters in the Psychopharmacology of Cannabinoids 410
    10.2 The Synapse—A Primary Site of Action? 417
    10.3 Final Comments 417

References 419

13 OCCURRENCE AND TREATMENT OF SOLVENT ABUSE IN CHILDREN AND ADOLESCENTS 431
H. G. Morton
1. Introduction 431
2. The Organic Solvents
    2.1 Pharmacology and Toxicology 433
    2.2 Toxicity of Organic Solvents 434
3. The Epidemiology of Solvent Abuse 434
4. Solvent Abusers and Their Behavior 435
5. The Clinical Features of Solvent Abuse 438
6. The Physical Complications of Solvent Abuse
    6.1 Encephalopathy 438
    6.2 Cerebellar Degeneration 439
    6.3 Peripheral Neuropathy 439
    6.4 Other Neurological Complications 439
    6.5 Miscellaneous 440
7. Sudden Death Resulting from Solvent Abuse 440
8. Psychological and Psychiatric Aspects of Solvent Abuse 441
9. The Relationship between Abuse of Solvents and Abuse of Alcohol and Other Drugs 443
10. The Management of Solvent Abuse in Children and Adolescents
    10.1 Management of the Individual Solvent Abuser 443
    10.2 Community Approaches to the Management of Solvent Abuse 445
11. Conclusion 447
References 447

14 NICOTINE AS THE BASIS OF THE SMOKING HABIT 453
D. J. K. Balfour
1. Introduction 453
2. Evidence Implicating Nicotine in the Tobacco Smoking Habit
    2.1 Studies Directed at Demonstrating a Role for Nicotine 453
    2.2 Other Factors Which Could Contribute to the Tobacco Smoking Habit 456
3. Studies on the Effects of Nicotine in Humans
    3.1 The Effects of Nicotine on Performance, Memory and Information Processing 457
    3.2 Electroencephalographic Studies 458
    3.3 Nicotine as a 'Tranquilizer' 459
4. Effects of Nicotine on Animal Behavior
    4.1 Spontaneous Behavior 460
    4.2 Effects of Nicotine on Operant Behavior for a Positive Reward 461

References 467